Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Completed · Phase 3

Conditions studied: Pneumococcal Vaccines

In brief

The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.

Key facts

Study ID

NCT00574548

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

720

Starts

2007-11-01

Expected to finish

2010-02-01

Last updated by the study team

2011-07-22

Who can join

Age: 60 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or Female, aged 60 to 64 years.
• Healthy.

You may not qualify if…

• Previous vaccination with any licensed or experimental pneumococcal vaccine.
• History of severe adverse reaction associated with a vaccine.
• Immunodeficiency.

Where it is running

• Pfizer Investigational Site — Chandler, Arizona, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — Boise, Idaho, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Bristol, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.